Competing endogenous RNA network in newly diagnosed multiple myeloma by genetic microarray

Competing endogenous RNA network in newly diagnosed multiple myeloma by genetic microarray

Bibliographic Details
Main Authors:	Yu-Qin He, Zhi-Yao Zhang, Hui-Xing Zhou, Fang Ye, Wen-Ming Chen, Peng Lyu
Format:	Article
Language:	English
Published:	Wolters Kluwer 2020-11-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000001108

Similar Items

Newly diagnosed multiple myeloma in Taiwan
by: Chung-King Lin, et al.
Published: (2009-07-01)

Daratumumab in untreated newly diagnosed multiple myeloma
by: Nadine Abdallah, et al.
Published: (2019-12-01)

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
by: Jingsong He, et al.
Published: (2014-01-01)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
by: Yue Zhang, et al.
Published: (2019-01-01)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
by: Kazuhito Suzuki, et al.
Published: (2016-11-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Changing landscape of induction therapy in newly diagnosed multiple myeloma
by: Nidhi Tandon, et al.
Published: (2019-01-01)

Survival Analysis of Total Therapy 3 in Newly Diagnosed Multiple Myeloma
by: Miller, Scott Edward Bowman
Published: (2015)

Identifying responders to melphalan and dexamethasone for newly diagnosed multiple myeloma patients
by: Esmaeili, Abbas
Published: (2008)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
by: Larysa Sanchez, et al.
Published: (2021-01-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: E. Zamagni, et al.
Published: (2020-12-01)

Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
by: Benjamin A. Derman, et al.
Published: (2018-01-01)

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients
by: Hu Y, et al.
Published: (2019-11-01)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
by: Roberto Ria, et al.
Published: (2012-01-01)

Endocarditis due to Gemella haemolysans in a newly diagnosed multiple myeloma patient
by: Dongyan Liu, et al.
Published: (2016-09-01)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
by: Bengoechea, E., et al.
Published: (2022)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Induction therapy in newly diagnosed multiple myeloma: Current research scenario and questions for the future
by: Bhausaheb Bagal, et al.
Published: (2019-01-01)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
by: Sarah A. Bird, et al.
Published: (2020-05-01)

Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics
by: Chenyao Lin, et al.
Published: (2020-09-01)

Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study
by: Rikke Faebo Larsen, et al.
Published: (2020-03-01)

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling
by: Benjamin W. Teh, et al.
Published: (2017-10-01)

POS-201 INFECTIOUS COLITIS DEVELOPING IN TWO PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA
by: B. MARIEM, et al.
Published: (2021-04-01)

Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma
by: Doaa A. Mohammed, et al.
Published: (2021-06-01)

Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
by: Kylee H. Maclachlan, et al.
Published: (2021-08-01)

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation
by: Ma K, et al.
Published: (2021-04-01)

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods
by: Zhang HM, et al.
Published: (2019-09-01)

Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
by: Ying Tian, et al.
Published: (2018-01-01)

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
by: Rafael Fonseca, et al.
Published: (2020-11-01)

A rare case of newly diagnosed multiple myeloma presenting to the emergency department with acute paraplegias
by: Sunay Yıldırım, et al.
Published: (2019-12-01)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
by: Samrat Roy Choudhury, et al.
Published: (2020-08-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
by: Shenghao Wu, et al.
Published: (2015-01-01)

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
by: Offidani M, et al.
Published: (2014-09-01)

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
by: Alegre, A., et al.
Published: (2022)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
by: JingSong He, et al.
Published: (2021-07-01)

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
by: Mark T Drayson, et al.
Published: (2019-11-01)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020-12-01)

Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
by: Liping Fan, et al.
Published: (2017-01-01)

Cannot write session to /tmp/vufind_sessions/sess_1kalld6rjroqb58qthjnt9dd9b